Pfizer has appointed Meenakshi Nevatia as the Managing Director and Additional Director, effective April 3, 2023 for five years. She succeeds SSridhar, who announced his early retirement in August 2022.

Nevatia has nearly 30 years of business leadership and consulting

experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and more recently Stryker Corporation. Meenakshi has worked in over eight countries (developed and emerging) and has held several General Management roles across multiple markets such as Thailand, Spain (Iberia) and India.

Nevatia received her Bachelor’s in Science (Economics) from Presidency College, Kolkata, and completed her Post Graduate Diploma in Management from the highly acclaimed Indian Institute of Management Ahmedabad (IIMA)

Pradip Shah, Chairman of the Board, Pfizer said “This is a pivotal time for Pfizer in India, and I am pleased to welcome Nevatiato take over the baton and set new benchmarks for the company and indeed the industry, I also wish to express my gratitude to Sridhar for his long years of service. His patient-centric vision contributed significantly to the growth of the company, increasing our reach to many more patients in the country and helping them benefit from the company’s drugs and therapies over the years. 

Nick Lagunowich, Global President, Emerging Markets Pfizer said, “India is critical to the healthcare ecosystem in the region and globally; it is a place where we aspire to bring many more breakthrough therapies and health solutions to patients across the economic segments. We are thrilled to welcome Meenakshi who comes at an important time when we are poised to scale up our contribution to the India healthcare industry.”